Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ChemBridge, a contract research organization, has announced new multi-year research collaboration in discovery chemistry with AstraZeneca, an international healthcare business engaged in research, development, manufacturing and marketing of prescription pharmaceuticals.
Subscribe to our email newsletter
In accordance with the new agreement scientists from ChemBridge and AstraZeneca will work together to design and develop a new generation of highly advanced, research intensive small molecule libraries that further enhance AstraZeneca’s global drug discovery effort.
This new alliance follows the previous collaboration between ChemBridge and AstraZeneca that was established in 2006 and successfully completed earlier in 2008.
Tony Wilkinson, vice president of lead generation DECS at AstraZeneca, said:”The success of our previous collaboration demonstrated the capabilities ChemBridge and CRL have in drug discovery chemistry and library synthesis. With our new alliance we are confident that this more challenging project will be executed with similar success.”